Autor según el artículo: Javier Luque; Marta Sanchis; Mariana Castanheira; Adela Martin-Vicente; Deanna A. Sutton; Annette W. Fothergill; Nathan P. Wiederhold; Josep Guarro
Departamento: Ciències Mèdiques Bàsiques
Autor/es de la URV: CAPILLA LUQUE, JAVIER; Marta Sanchis; Mariana Castanheira; Adela Martin-Vicente; Deanna A. Sutton; Annette W. Fothergill; Nathan P. Wiederhold; GUARRO ARTIGAS, JOSEP
Palabras clave: voriconazole fungal infection Candida glabrata
Resumen: In this study, 27 clinical isolates of Candida glabrata with voriconazole (VRC) minimum inhibitory concentrations (MICs) ranging from ¿0.03 ¿g/mL to 8 ¿g/mL were tested to determine whether in vitro data are predictive of in vivo efficacy. The efficacy of VRC administered at 40 mg/kg was assayed in a neutropenic murine model of disseminated infection by C. glabrata. The reduction in fungal tissue burden in the kidneys was used as a marker of treatment efficacy. VRC reduced the fungal tissue burden in mice infected with strains that had MICs below the epidemiological cut-off value (ECV) of 0.25 ¿g/mL. Variable efficacy of VRC was obtained when the MIC equalled the ECV, and VRC was ineffective when the MIC exceeded the ECV. These results suggest that the use of in vitro data could be useful to predict the outcome for infections by this fungus.
Grupo de investigación: Unitat de Micologia i Microbiologia Ambiental
Áreas temáticas: Health sciences Ciencias de la salud Ciències de la salut
Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
ISSN: 0924-8579
Identificador del autor: 0000-0002-0765-6403; 0000-0002-7839-7568
Fecha de alta del registro: 2016-05-24
Página final: 288
Volumen de revista: 47
Versión del articulo depositado: info:eu-repo/semantics/acceptedVersion
URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
Entidad: Universitat Rovira i Virgili
Año de publicación de la revista: 2016
Página inicial: 286
Tipo de publicación: Article Artículo Article
Repositori URV